Group One Trading’s MoonLake Immunotherapeutics MLTX Stock Holding History

Group One Trading’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.49M	Buy	80,200 +20,600	+35%	+$341K	﹤0.01%	2346
2025 Q4	$786K	Sell	59,600 -106,700	-64%	-$1.26M	﹤0.01%	3111
2025 Q3	$1.19M	Buy	166,300 +138,900	+507%	+$7.24M	﹤0.01%	2848
2025 Q2	$1.29M	Sell	27,400 -13,400	-33%	-$546K	﹤0.01%	2535
2025 Q1	$1.59M	Sell	40,800 -43,300	-51%	-$1.87M	﹤0.01%	2037
2024 Q4	$4.55M	Buy	84,100 +15,700	+23%	+$802K	0.01%	1235
2024 Q3	$3.45M	Buy	68,400 +64,000	+1,455%	+$3M	0.01%	1293
2024 Q2	$193K	Sell	4,400 -8,100	-65%	-$343K	﹤0.01%	3420
2024 Q1	$628K	Sell	12,500 -10,900	-47%	-$591K	﹤0.01%	2521
2023 Q4	$1.41M	Buy	23,400 +18,000	+333%	+$928K	﹤0.01%	2148
2023 Q3	$308K	Buy	+5,400	New	+$298K	﹤0.01%	3417

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Group One Trading's MLTX Position: Q1 2026 in Review

Group One Trading reduced its MoonLake Immunotherapeutics (MLTX) stake by 29% in Q1 2026, selling an estimated $148K and leaving 21,563 shares worth $402K. The position accounts for ﹤0.01% of the portfolio, ranked #3544.

Group One Trading first reported a position in MLTX in Q3 2023 and has held it in 6 quarters since. The position peaked at $679K in Q1 2024. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

Group One Trading held 21,563 shares of MoonLake Immunotherapeutics worth $402K as of Q1 2026.
Group One Trading sold 8,913 MoonLake Immunotherapeutics shares in Q1 2026, an estimated $148K.
MoonLake Immunotherapeutics made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #3544 holding.
Group One Trading first reported a position in MoonLake Immunotherapeutics in Q3 2023 and has held it in 6 quarters since.
Group One Trading's MoonLake Immunotherapeutics position peaked at $679K in Q1 2024.
147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.